ClinicalTrials.gg
CompletedNCT04444752Updated Aug 1, 2023Results posted

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of CBP-201 and placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Connect Biopharm LLC. Completed at 59 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
151st of 544
226 · median 96
Started
2020
with 36 others
Phase 2
202 of 639
18 open now
Registered
379th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 151st largest by enrollment of the 544 interventional ones that give a count, is one of 37 that started in 2020, is one of 202 in phase 2, and was the 379th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, dose regimen finding study to assess the efficacy, safety, and steady-state PK profile of CBP-201 administered to eligible adult subjects with moderate to severe atopic dermatitis compared to placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into a treatment period of 16 weeks and a follow-up period of 8 weeks.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be an adult ≥18 and ≤ 75 years of age at the screening visit (Screening) with atopic dermatitis according to American Academy of Dermatology Consensus Criteria, (Eichenfield 2014)
  2. Present for at least 1 year prior to the baseline visit (Baseline) with an inadequate response, in the judgement of the Investigator, to AD treatment with a topical regimen of , phosphodiesterase inhibitors or calcineurin inhibitors, or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effect or safety risks)
  3. Investigator Global Assessment (IGA) score ≥ 3 at Screening and Baseline.
  4. Eczema Area and Severity Index (EASI) score ≥ 16 at Screening and Baseline
  5. Body Surface Area (BSA) for total AD involvement ≥ 10% at Screening and Baseline
  6. Able and willing to apply a stable dose of a bland emollient twice a day to affected areas for at least 7 days before Baseline and to continue for the duration of the study
  7. Females of (FCBP) and males who have not undergone a vasectomy must abstain from heterosexual activities or agree to use effective throughout the entire study period.

Exclusion criteria

Exclusion Criteria:

  1. Have any of the following laboratory abnormalities at Screening:

    1. ≤ 90% of the lower limit of normal range (LLN)
    2. White blood cell (WBC) below the LLN
    3. below the LLN
    4. count below the LLN
  2. Have undergone treatment with any of the following:

    1. Topical agents such as , phosphodiesterase (PDE) inhibitors, Janus kinase (JAK) inhibitors, tacrolimus or pimecrolimus within 1 week prior to Baseline. Note that low to medium potency topical corticosteroids (TCS) are permitted after randomization to treat AD flares
    2. Prior treatment with dupilumab or any antibody against IL-4Rα or IL-13
    3. Systemic treatment for AD or other condition with steroids or other /immunomodulating substances, e.g., cyclosporine, mycophenolate-mofetil, azathioprine, methotrexate or oral Janus kinase (JAK) inhibitors within 4 weeks prior to Baseline. Use of steroid inhalers and nasal corticosteroids is allowed.
    4. Cell depleting agents, e.g. rituximab, within 6 months of Baseline or treatment with other biologics within 5 half-lives (if known) or 3 months prior to baseline visit, whichever is longer
    5. Phototherapy (narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + ultraviolet A [PUVA]), tanning beds, or any other light emitting device (LED), within 4 weeks of Baseline
    6. ≥ 2 bleach baths within 2 weeks of Baseline
    7. Prescription emollient to treat AD (e.g. Atopiclair®, MimyX®, Epicerum®, etc.) within 2 weeks of Baseline
    8. Any drug within 30 days or within 5 half-lives, whichever is longer, before Baseline.
    9. Live (attenuated) vaccine within 8 weeks of Baseline.
    10. Treatment with systemic traditional Chinese medicine (TCM) or herbal medications within 4 weeks before Baseline or treatment with topical TCM or herbal medications within 1 week before Baseline visit
  3. Have any of the following:

    1. Infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before Baseline, or superficial skin infection, such as impetigo, within 2 weeks before the Baseline (subjects may be rescreened after the infection has resolved)
    2. A history of parasitic infection (e.g. helminth), within 6 months of Baseline
    3. Per investigator judgement, known or suspected history of immunosuppression within 6 months of Baseline, including a history of invasive opportunistic infections, such as aspergillosis, coccidioidomycosis, histoplasmosis, (HIV), listeriosis, pneumocystosis, or tuberculosis, despite infection resolution; or unusually frequent, recurrent or prolonged infections.
    4. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC)
    5. A history of with the following exceptions: completely treated carcinoma in situ of cervix or non- squamous or basal cell carcinoma of the skin
    6. Positive results at Screening for surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or antibody with positive HCV RNA polymerase chain reaction; positive HIV serology at screening
    7. An allergy to L-histidine, trehalose or Tween (polysorbate) 80
  4. Women must not be pregnant, planning to become pregnant or breast-feed during the study
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    CBP-201 Dose 1

    CBP-201 Dose 1 subcutaneous (SC) injection

    Drug: CBP-201

  • Experimental
    CBP-201 Dose 2

    CBP-201 Dose 2 subcutaneous (SC) injection

    Drug: CBP-201

  • Experimental
    CBP-201 Dose 3

    CBP-201 Dose 3 subcutaneous (SC) injection

    Drug: CBP-201

  • Placebo comparator
    placebo

    subcutaneous (SC) injection

    Drug: placebo

Interventions

  • CBP-201 subcutaneous(SC) injection.

  • Drugplacebo

    subcutaneous(SC) injection

06

What researchers measure

Primary outcomes

  1. Percent Reduction in EASI Score From Baseline to Week 16

    EASI=Eczema Area Severity Index is a validated physician score for signs of atopic dermatitis. EASI can range from 0 to 72. An EASI score of 0 indicates clear/no eczema, 0.1 to 1.0 almost clear, 1.1 to 7 mild disease, 7.1 to 21 moderate disease, 21.1 to 50 severe disease, and 51-72 indicates very severe disease. EASI Sub-scale ranges are as follows: Head/neck can range from 0-7.2, Trunk 0-14.4, Upper Extremities 0-21.6, Lower Extremities can range from 0-28.8. To calculate EASI, % involvement is first assessed by body region with an Area involvement Score of 0-6 for each region: 0=0%, 1=1-9%, 2=10-29%, 3=30-39%, 4=50-69%, 5=70-89%, 6=90-100% involvement. Then 4 attributes (Erythema, Edema/Papulation, Excoriation, and Lichenification) are scored for severity (0= none, 1=mild, 2=moderate, 3=severe). A multiplier is applied head/neck=0.1, trunk=0.2, upper extremities= 0.3, lower extremities=0.4. The total EASI score is the sum of 4 regional sub-scores.

    Time frame: Reduction from baseline to 16 weeks

Secondary outcomes

  1. vIGA of 0/1 at Week 16

    Validated Investigator Global Assessment Score (vIGA) is assigned by the physician based on morphologic presentation of the disease in the clinic. The physician considers extent and severity of erythema, induration/papulation, lichenification, and oozing/crusting. A vIGA Score of 0=Clear, 1=Almost Clear, 2= Mild dermatitis, 3=Moderate dermatitis, and 4= Severe dermatitis. Patients are required to have a baseline IGA of 3 or 4. The response rate or percentage of patients achieving a vIGA of 0 or 1 (improved to clear or almost clear) at week 16 is the outcome.

    Time frame: Response Rate at 16 weeks

07

Results

Posted Aug 1, 2023

Participant flow

Patients were recruited based on physician referrral at academic and non-academic clinical centers between Jun 2020 and Sep 2021; 394 patients were screened. The first participant was randomized to treatment on 30 Jun 2020 and the last patient was randomized in April 2021. The last patient last visit was 22 Sept 2021.

Participant flow — Overall Study
MilestoneCBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlacebo
Started57575656
Completed46455040
Not completed1112616
Withdrew: Adverse event1002
Withdrew: Lost to follow-up2625
Withdrew: Physician decision0002
Withdrew: Pregnancy0001
Withdrew: Withdrawal by subject6534
Withdrew: Protocol violation1100
Withdrew: Patient moving out of town1001
Withdrew: Lack of efficacy0001
Withdrew: Death0010

Outcome measures

PrimaryPercent Reduction in EASI Score From Baseline to Week 16

EASI=Eczema Area Severity Index is a validated physician score for signs of atopic dermatitis. EASI can range from 0 to 72. An EASI score of 0 indicates clear/no eczema, 0.1 to 1.0 almost clear, 1.1 to 7 mild disease, 7.1 to 21 moderate disease, 21.1 to 50 severe disease, and 51-72 indicates very severe disease. EASI Sub-scale ranges are as follows: Head/neck can range from 0-7.2, Trunk 0-14.4, Upper Extremities 0-21.6, Lower Extremities can range from 0-28.8. To calculate EASI, % involvement is first assessed by body region with an Area involvement Score of 0-6 for each region: 0=0%, 1=1-9%, 2=10-29%, 3=30-39%, 4=50-69%, 5=70-89%, 6=90-100% involvement. Then 4 attributes (Erythema, Edema/Papulation, Excoriation, and Lichenification) are scored for severity (0= none, 1=mild, 2=moderate, 3=severe). A multiplier is applied head/neck=0.1, trunk=0.2, upper extremities= 0.3, lower extremities=0.4. The total EASI score is the sum of 4 regional sub-scores.

Time frame:
Reduction from baseline to 16 weeks
Reported as:
Least squares mean · percent reduction from Baseline
Percent Reduction in EASI Score From Baseline to Week 16
percent reduction from BaselineCBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlacebo
Percent Reduction in EASI Score From Baseline to Week 1657.56 ± 4.61063.03 ± 4.96163.50 ± 4.66139.67 ± 4.638
Statistical analysis
  • CBP-201 300 Q2W vs Placebo · ANCOVA · p = 0.0007 (Adjusted for multiplicity using a serial gatekeeping procedure at the 5% in descending order: 1. 300 mg dose Q2W 2. 150 mg dose Q2W 3. 300 mg dose Q4W vs placebo) · Mean difference (final values): 23.36The data were analyzed using an ANCOVA model adjusted for treatment, baseline vIGA (moderate, severe), and baseline EASI.
  • CBP-201 150 Q2W vs Placebo · ANCOVA · p = 0.0067 (Adjusted for multiplicity using a serial gatekeeping procedure at the 5% in descending order: 1. 300 mg dose Q2W 2. 150 mg Q2W 3. 300 mg Q4W vs placebo.) · Mean difference (final values): 17.89The data were analyzed using an ANCOVA model with terms for treatment, baseline vIGA (moderate, severe), and baseline EASI.
  • CBP-201 300 Q4W vs Placebo · ANCOVA · p = 0.0004 (Adjusted for mulitplicity using a serial gatekeeping procedure at the 5% in descending order: 1. 300 mg dose Q2W 2. 150 mg Q2W 3. 300 mg Q4W vs placebo.) · Mean difference (final values): 23.83The data were anlayzed using an ANCOVA model with terms for treatment, baseline vIGA (moderate, severe), and baseline EASI
SecondaryvIGA of 0/1 at Week 16

Validated Investigator Global Assessment Score (vIGA) is assigned by the physician based on morphologic presentation of the disease in the clinic. The physician considers extent and severity of erythema, induration/papulation, lichenification, and oozing/crusting. A vIGA Score of 0=Clear, 1=Almost Clear, 2= Mild dermatitis, 3=Moderate dermatitis, and 4= Severe dermatitis. Patients are required to have a baseline IGA of 3 or 4. The response rate or percentage of patients achieving a vIGA of 0 or 1 (improved to clear or almost clear) at week 16 is the outcome.

Time frame:
Response Rate at 16 weeks
Reported as:
Count of participants · Participants
vIGA of 0/1 at Week 16
ParticipantsCBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlacebo
vIGA of 0/1 at Week 16916115
Statistical analysis
  • CBP-201 300 Q2W vs Placebo · Chi-squared · p = 0.0089 (There were no adjustments for multiple comparisons. For IGA response, counts, percentage, and 95% CIs obtained using the Clopper-Pearson method and were presented for pairwise comparisons for each CBP-201 group vs. placebo.) · Difference in viga response rate: 28.1

Adverse events

Collected over Adverse events were reported from the time the subject signed the informed consent and continued through the scheduled last visit (32 weeks after baseline visit), or if unresolved, until clinical recovery was complete.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CBP-201 150 Q2W0/57 (0%)1/57 (1.8%)26/57 (45.6%)
CBP-201 300 Q2W0/57 (0%)0/57 (0%)21/57 (36.8%)
CBP-201 300 Q4W1/56 (1.8%)2/56 (3.6%)34/56 (60.7%)
Placebo0/56 (0%)2/56 (3.6%)31/56 (55.4%)
Most frequent serious events
Most frequent serious events
EventCBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlacebo
CholelithiasisHepatobiliary disorders0/570/570/561/56
PneumoniaInfections and infestations0/570/570/561/56
Angina pectorisCardiac disorders0/570/571/560/56
Cardiac arrestCardiac disorders0/570/571/560/56
Rib fractureInjury, poisoning and procedural complications0/570/571/560/56
NauseaGastrointestinal disorders1/570/570/560/56
VomitingGastrointestinal disorders1/570/570/560/56
HeadacheNervous system disorders1/570/570/560/56
Most frequent other events
Showing 10 of 15
Most frequent other events
EventCBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlacebo
Dermatitis atopicSkin and subcutaneous tissue disorders7/575/5714/568/56
COVID-19Skin and subcutaneous tissue disorders4/572/571/564/56
NasopharyngitisInfections and infestations1/573/572/564/56
HeadacheNervous system disorders3/572/574/560/56
Urinary tract infectionInfections and infestations4/571/570/561/56
Upper respiratory tract infectionInfections and infestations1/571/573/561/56
Skin infectionInfections and infestations0/570/571/563/56
NauseaGastrointestinal disorders1/572/573/560/56
Vision blurredEye disorders0/570/570/562/56
Back painMusculoskeletal and connective tissue disorders0/570/572/562/56

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlaceboTotal
<=18 years00000
Between 18 and 65 years52545254212
>=65 years534214
Age, Continuous
Age, Continuous(years)CBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlaceboTotal
Mean39.5 ± 15.9839.6 ± 14.7941.7 ± 15.2239.6 ± 14.7940.1 ± 15.13
Sex: Female, Male
Sex: Female, Male(Participants)CBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlaceboTotal
Female30272836121
Male27302820105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlaceboTotal
Hispanic or Latino1724272492
Not Hispanic or Latino40332932134
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlaceboTotal
American Indian or Alaska Native00011
Asian179121452
Native Hawaiian or Other Pacific Islander11013
Black or African American8710631
White30383232132
More than one race01113
Unknown or Not Reported11114
Region of Enrollment
Region of Enrollment(participants)CBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlaceboTotal
New Zealand535619
United States40474144172
China1169632
Australia11103
EASI Score
EASI Score(units on a scale)CBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlaceboTotal
Mean24.61 ± 10.47127.57 ± 11.77623.08 ± 8.21825.16 ± 9.02125.11 ± 10.042
IGA Score
IGA Score(Participants)CBP-201 150 Q2WCBP-201 300 Q2WCBP-201 300 Q4WPlaceboTotal
IGA 3 = Moderate disease43344039156
IGA 4 = Severe disease1423161770

1 further baseline measures are reported on the registry.

08

Study locations

59 sites
  • Connect Investigative Site 310
    Glendale, Arizona 85308, United States
  • Connect Investigative Site 338
    Phoenix, Arizona 85001, United States
  • Connect Investigative Site 316
    Tempe, Arizona 85284, United States
  • Connect Investigative Site 305
    Little Rock, Arkansas 72204, United States
  • Connect Investigative Site 327
    Canoga Park, California 91303, United States
  • Connect Investigative Site 324
    Encinitas, California 92024, United States
  • Connect Investigative Site 301
    Fremont, California 94538, United States
  • Connect Investigative Site 312
    Huntington Beach, California 92647, United States
  • Connect Investigative Site 329
    Mission Viejo, California 92691, United States
  • Connect Investigative Site 322
    San Diego, California 92123, United States
  • Connect Investigative Site 323
    San Luis Obispo, California 93405, United States
  • Connect Investigative Site 317
    Santa Ana, California 92703, United States
  • Connect Investigative Site 318
    Sherman Oaks, California 91403, United States
  • Connect Investigative Site 325
    Thousand Oaks, California 91320, United States
  • Connect Investigative Site 332
    Coral Gables, Florida 33144, United States
  • Connect Investigative Site 320
    Hialeah, Florida 33016, United States
  • Connect Investigative Site 306
    Hollywood, Florida 33021, United States
  • Connect Investigative Site 308
    Jacksonville, Florida 32256, United States
  • Connect Investigative Site 314
    Maitland, Florida 32751, United States
  • Connect Investigative Site 331
    Miami, Florida 33155, United States
  • Connect Investigative Site 337
    Miami, Florida 33155, United States
  • Connect Investigative Site 321
    Miami, Florida 33173, United States
  • Connect Investigative Site 304
    Orlando, Florida 32801, United States
  • Connect Investigative Site 340
    Weston, Florida 33331, United States
  • Connect Investigative Site 333
    Chicago, Illinois 60640, United States
  • Connect Investigative Site 303
    Chicago, Illinois 60660, United States
  • Connect Investigative Site 307
    New Albany, Indiana 47150, United States
  • Connect Investigative Site 313
    West Lafayette, Indiana 47906, United States
  • Connect Investigative Site 311
    Louisville, Kentucky 40241, United States
  • Connect Investigative Site 319
    Hunt Valley, Maryland 21030, United States
  • Connect Investigative Site 335
    Saint Joseph, Missouri 64506, United States
  • Connect Investigative Site 315
    Saint Louis, Missouri 63110, United States
  • Connect Investigative Site 336
    Las Vegas, Nevada 89109, United States
  • Connect Investigative Site 326
    Albuquerque, New Mexico 87102, United States
  • Connect Investigative Site 330
    Cincinnati, Ohio 45231, United States
  • Connect Investigative Site 328
    Rapid City, South Dakota 57702, United States
  • Connect Investigative Site 309
    Memphis, Tennessee 38119, United States
  • Connect Investigative Site 334
    Houston, Texas 77065, United States
  • Connect Investigative Site 111
    Canberra, Australian Capital Territory 2606, Australia
  • Connect Investigative Site 104
    Darlinghurst, New South Wales 2010, Australia
  • Connect Investigative Site 108
    Kanwal, New South Wales 2259, Australia
  • Connect Investigative Site 105
    Sydney, New South Wales 2289, Australia
  • Connect Investigative Site 101
    Brisbane, Queensland 4102, Australia
  • Connect Investigative Site 102
    Melbourne, Victoria 3002, Australia
  • Connect Investigative Site 106
    Fremantle, Western Australia 6160, Australia
  • Connect Investigative Site 103
    Perth, Western Australia 6009, Australia
  • Connect Investigative Site 408
    Beijing, Beijing 100020, China
  • Connect Investigative Site 404
    Beijing, Beijing 100050, China
  • Connect Investigative Site 405
    Wuxi, Jiangsu 214002, China
  • Connect Investigative Site 409
    Zhenjiang, Jiangsu 212001, China
  • Connect Investigative Site 402
    Jinan, Shandong 250013, China
  • Connect Investigative Site 401
    Shanghai, Shanghai 200040, China
  • Connect Investigative Site 406
    Shanghai, Shanghai 200071, China
  • Connect Investigative Site 410
    Tianjin, Tianjin 300120, China
  • Connect Investigative Site 403
    Hangzhou, Zhejiang 310003, China
  • Connect Investigative Site 204
    Tauranga, Bay Of Plenty 3110, New Zealand
  • Connect Investigative Site 202
    Havelock North, Hawke's Bay 4130, New Zealand
  • Connect Investigative Site 205
    Waikanae, Kapiti Coast 5036, New Zealand
  • Connect Investigative Site 203
    Auckland, 1010, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jul 2021, 12 months.

Results were first posted in Aug 2023, 2 years after primary completion.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 24, 2020
StartActual
Jul 17, 2020
Primary completionActual
Jul 28, 2021
CompletionActual
Sep 22, 2021
Results first posted
Aug 1, 2023
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04444752
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Jun 24, 2020
Start date
Jul 17, 2020
Primary completion
Jul 28, 2021
Completion
Sep 22, 2021
Results posted
Aug 1, 2023
Last update
Aug 1, 2023

Study contacts

Suzhou Connect
study director · Connect Biopharm LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion